← Back to all signals
RESEARCH PAPER ANALYSIS

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

AI interpretation is pending for this paper.

Open original publication →
PMID40241281
JournalNeuro-oncology
Publication Date2025-10-14
Ingested2026-08-02 12:05 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: PBTC-029B was a phase 2 trial evaluating efficacy of selumetinib in children with recurrent/progressive low-grade glioma. We report results of strata 2, 5, and 6 with updated survivals for strata 1, 3, and 4. METHODS: Stratum 2 included recurrent/progressive pilocytic astrocytoma (PA) not associated with neurofibromatosis type-1 (NF1) that screened negative for the BRAF-KIAA1549 fusion and BRAFV600E mutation. Stratum 5 enrolled non-PA that screened positive for one of the BRAF aberrations. Stratum 6 enrolled children who consented to tissue screening, but there was an assay failure. For long-term survivals, stratum 1 included non-NF1 PA positive for one of the BRAF aberrations; stratum 3 included NF1-associated pLGG; and stratum 4 included non-NF1 optic pathway/hypothalamic tumors. RESULTS: Stratum 2: among 14 evaluable patients, there was 1 partial response (PR), 7 stable disease (SD), and 6 progressive disease (PD); the overall response rate (ORR) was 7.1%. Two-year progression-free survival (PFS)/overall survival (OS) were 57.1%/100%, respectively. Stratum 5: among 23 evaluable patients, there was 1 complete response (CR), 4 PR, 12 SD, and 6 PD; ORR was 21.7%. Two-year PFS/OS were 74.8%/100%, respectively. Stratum 6: among 26 evaluable patients, there were 7 PR, 14 SD, and 5 PD; ORR was 26.9%. Two-year PFS/OS were 72.0%/100%, respectively. The median follow-up for patients on strata 1, 3, and 4 without events are 60.4, 60.4, and 58.1 months, and 5-year PFS/OS were 30.8%/88.9%, 54.2%/100%, and 51.0%/100%, respectively. CONCLUSIONS: Selumetinib provided stability and responses across many pLGG subgroups, and some patients achieved prolonged disease control without additional therapy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Fear of Recurrence and Medication Adherence in Pediatric Leukaemia Survivors in Low-Resource Settings. Juntendo medical journal 70.8 2 Histopathologically Compatible Neurocysticercosis Mimicking an Intracranial Tumor in a Child. Iranian journal of parasitology 60.8 3 Direct medical costs of chronic diseases in Jordan: a systematic review. Health economics review 71.5 4 Panniculitis masquerading as generalised lymphadenopathy in a neonate: a diagnostic dilemma - a case report and a mini review. BMC pediatrics 49.0 5 The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes. Journal of cannabis research 81.79 6 Integrating Pediatric Dentistry Into Multidisciplinary Palliative Care for Pediatric Oral Cancer Patients: A Scoping Review. Sage open pediatrics 60.8 7 [Clinical characteristics in different age subgroups of non-pregnant young patients with papillary thyroid carcinoma]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 63.9 8 Unusual presentation of pediatric lichen planus with cutaneous, oral, and nail involvement: a case report. Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire : JCHD 49.9 9 Sex differences in gastrointestinal cancers incidence and mortality among adolescents and young adults in China: an age-period-birth cohort study. Journal of translational internal medicine 57.5 10 Diffuse brainstem gliomas across the pediatric, adolescent, and adult age spectrum: Clinical and radiological features, molecular profile, and determinants of survival in a multicenter retrospective cohort of 42 patients. Surgical neurology international 69.02 11 Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma. Communications medicine 54.9 12 Cervicothoracic intramedullary teratoma in a 6-year-old child: A case report. Surgical neurology international 45.5 13 Occipital interhemispheric transtentorial approach for microsurgical resection of a posterior fossa medulloblastoma: 2-dimensional operative video. Surgical neurology international 59.9 14 Calvarial erosion secondary to epithelioid glioblastoma: A molecularly characterized case report. Surgical neurology international 55.0 15 Longitudinal changes in bone mineral density, bone turnover markers, and body composition in children and adolescents treated for acute lymphoblastic leukemia. Frontiers in endocrinology 61.9 16 Case Report: Successful treatment of drug-resistant epilepsy with unilateral deep brain stimulation of the anterior nucleus of the thalamus. Frontiers in neuroscience 58.0 17 Surgical resection combined with TACE for primary clear cell carcinoma of the liver: a case report and literature review. Frontiers in surgery 49.9 18 Hypomorphic biallelic LIFR variants define a multisystem disorder with survival beyond infancy and hyperinflammatory vulnerability. Frontiers in immunology 61.72 19 Cancer Stem Cells in Drug Delivery Strategies: Current Advances and Future Directions. Current drug delivery 62.16 20 Calcified choroid plexus papilloma of the temporal horn presenting with seizures in an adult without hydrocephalus: An illustrative case. Surgical neurology international 59.9 21 TRIM65-BTG3-HIF-1α axis drives osteosarcoma progression via M2 macrophage polarization and angiogenesis. Journal of translational internal medicine 53.4 22 Pediatric Leptomeningeal Glial Tumors: A Retrospective Case Series and Review of the Literature. Turkish archives of pediatrics 63.3 23 Management of Obesity in Special Populations and Limited-Resource Settings: An Egyptian Medical Position Statement. Diabetes, metabolic syndrome and obesity : targets and therapy 61.9 24 Voxelwise white-matter compositional connectivity mapping from diffusion MRI via reliability-aware hierarchical inference. Medical image analysis 56.0 25 The visible and invisible scars of childhood cancer: A qualitative study of body image and identity in survivorship. British journal of health psychology 59.6 26 Cytogenetic Landscape of Complex Karyotypes Across Hematological Malignancies: Common and Disease-Specific Patterns in a Large Single-Center Cohort. Genes, chromosomes & cancer 63.7 27 Dynamics of the Prevalence of Non-communicable Diseases in the Urban Double Cotonou - Abomey-Calavi (South of Benin). The Nigerian postgraduate medical journal 38.5 28 Validation of Modified Albumin-Bilirubin-Tumor Stage as a Prognostic Model in Early-Stage Hepatocellular Carcinoma Treated With Radiofrequency Ablation. The Kaohsiung journal of medical sciences 70.5 29 A 17-cm ileocecal inflammatory myofibroblastic tumor with severe inflammatory syndrome in a child: a case report. Journal of surgical case reports 45.5 30 Giant Lipoma of the Thoracic Wall in a Two-Year-Old Girl: Imaging Features Supporting a Benign Diagnosis. Cureus 57.5 31 Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cell Transplantation Program for Patients With Hematologic Malignancy in a Resource-Limited Center in Chile. Annals of transplantation 69.1 32 Children of advanced cancer patients need better support: A case report. Palliative & supportive care 49.5
PATIENT-FRIENDLY SUMMARY

A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic